0mg
0mg
First Flying Electric Ferry in the U.S. is Coming to Lake TahoeRAHWAY, N.J.--(BUSINESS WIRE)--Nov 22, 2024-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that TRC Capital Investment Corporation (TRC Capital) has commenced an unsolicited “mini-tender” offer, dated November 12, 2024, to purchase up to 1,000,000 shares of Merck common stock at $96.38 per share. The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024 ($100.73), the last trading day before the date of the offer, and approximately 3.48% below the closing price of the Merck common stock on November 21, 2024 ($99.86), the day prior to this release. Merck does not endorse TRC Capital’s offer and recommends that Merck shareholders reject the offer and not tender their shares in response to TRC Capital’s unsolicited mini-tender offer. This mini-tender offer is at a price below the closing price for Merck’s shares (as of the day prior to this release) and is subject to numerous conditions, including TRC Capital’s ability to obtain financing. Merck is not associated in any way with TRC Capital, its mini-tender offer or the offer documentation. TRC Capital has made similar unsolicited mini-tender offers for shares of other publicly traded companies. Mini-tender offers seek to acquire less than 5% of a company's outstanding shares. This lets the offering company avoid many of the disclosure and procedural requirements the U.S. Securities and Exchange Commission (SEC) requires for tender offers. As a result, mini-tender offers do not provide investors the same level of protections as provided by larger tender offers under U.S. federal securities laws. On its website , the SEC advises that the people behind mini tender-offers “frequently use mini-tender offers to catch shareholders off guard” and that investors “may end up selling at below-market prices.” The SEC's website also contains important tips for investors regarding mini-tender offers. Like TRC Capital’s other offers, this one puts individual investors at risk because they may not realize they are selling their shares at a discount. Merck urges shareholders to obtain current stock quotes for their shares of Merck common stock, to review the terms and conditions of the offer, to consult with their brokers or financial advisers, and to exercise caution with respect to TRC Capital’s mini-tender offer. Merck shareholders who have already tendered are advised they may withdraw their shares by following the procedures for withdrawal described in the TRC Capital offer documents prior to the expiration of the offer, which is currently scheduled for 11:59 a.m. EST on December 11, 2024. Merck encourages brokers, dealers, and other investors to review the SEC’s letter regarding broker-dealer mini-tender offer dissemination and disclosure. Merck requests that a copy of this news release be included with all distribution of materials related to TRC Capital’s offer for shares of Merck common stock. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter) , Facebook , Instagram , YouTube and LinkedIn . Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ). View source version on businesswire.com : https://www.businesswire.com/news/home/20241122275388/en/ CONTACT: Media Contacts:Robert Josephson (203) 914-2372 robert.josephson@merck.comMichael Levey (215) 872-1462 michael.levey@merck.comInvestor Contacts:Peter Dannenbaum (732) 594-1579 peter.dannenbaum@merck.comSteven Graziano (732) 594-1583 steven.graziano@merck.com KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH FINANCE GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Merck & Co., Inc. Copyright Business Wire 2024. PUB: 11/22/2024 04:17 PM/DISC: 11/22/2024 04:17 PM http://www.businesswire.com/news/home/20241122275388/en
Cowboys set to host Bengals under open roof after falling debris thwarted that plan against TexansC$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 TORONTO , Dec. 9, 2024 /PRNewswire/ - Manulife has been notified of an unsolicited mini-tender offer made by New York Stock and Bond LLC (New York Stock and Bond) to purchase up to 50,000 Manulife common shares, or less than 0.003% of the common shares outstanding, at a price of USD$12.50 per share. Manulife is in no way associated with New York Stock and Bond and does not recommend or endorse acceptance of this unsolicited offer. Manulife cautions shareholders that the mini-tender offer has been made at a price below the current market price for Manulife shares. The offer represents a discount of approximately 60.76% and 60.80%, respectively, below the closing prices of Manulife common shares on the TSX and NYSE on November 27, 2024 , the last trading day before the mini-tender offer was commenced, and a discount of 61.43% and 61.42%, respectively, below the closing prices on the TSX and NYSE on December 6, 2024 . Mini-tender offers are designed to seek less than 5% of a company's outstanding shares, avoiding disclosure and procedural requirements applicable to most bids under Canadian and U.S. securities regulations. The Canadian Securities Administrators (CSA) and the U.S. Securities and Exchange Commission (SEC) have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities. The SEC states that "bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price." Shareholders should carefully review the New York Stock and Bond offer documents and current market price for Manulife shares, and consult their investment advisors regarding any offer they may receive and review with their advisors all options for their investment in Manulife shares. Manulife has stock transfer agents providing shareholder services in Canada , the United States , Hong Kong and the Philippines . These local agents provide services directly to our registered shareholders and can provide information on share account management, direct deposit of dividends, dividend reinvestment and share purchase plans. Please email manulifeinquiries@tmx.com for more information. Manulife requests that a copy of this news release be included in any distribution of materials relating to New York Stock and Bond's mini-tender offer for Manulife common shares. About Manulife Manulife Financial Corporation is a leading international financial services provider, helping people make their decisions easier and lives better. With our global headquarters in Toronto, Canada , we provide financial advice and insurance, operating as Manulife across Canada , Asia , and Europe , and primarily as John Hancock in the United States . Through Manulife Investment Management, the global brand for our Global Wealth and Asset Management segment, we serve individuals, institutions, and retirement plan members worldwide. At the end of 2023, we had more than 38,000 employees, over 98,000 agents, and thousands of distribution partners, serving over 35 million customers. We trade as 'MFC' on the Toronto , New York , and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/manulife-cautions-investors-regarding-new-york-stock-and-bond-llc-offer-for-shares-302326646.html SOURCE Manulife Financial Corporation
Social media users are misrepresenting a report released Thursday by the Justice Department inspector general's office, falsely claiming that it's proof the FBI orchestrated the Capitol riot on Jan. 6, 2021. The watchdog report examined a number of areas, including whether major intelligence failures preceded the riot and whether the FBI in some way provoked the violence. Claims spreading online focus on the report's finding that 26 FBI informants were in Washington for election-related protests on Jan. 6, including three who had been tasked with traveling to the city to report on others who were potentially planning to attend the events. Although 17 of those informants either entered the Capitol or a restricted area around the building during the riot, none of the 26 total informants were authorized to do so by the bureau, according to the report. Nor were they authorized to otherwise break the law or encourage others to do so. Here's a closer look at the facts. CLAIM: A December 2024 report released by the Department of Justice's Office of the Inspector General is proof that the Jan. 6 Capitol riot was a setup by the FBI. THE FACTS: That's false. The report found that no undercover FBI employees were at the riot on Jan. 6 and that none of the bureau's informants were authorized to participate. Informants, also known as confidential human sources, work with the FBI to provide information, but are not on the bureau’s payroll. Undercover agents are employed by the FBI. According to the report, 26 informants were in Washington on Jan. 6 in connection with the day's events. FBI field offices only informed the Washington Field Office or FBI headquarters of five informants that were to be in the field on Jan. 6. Of the total 26 informants, four entered the Capitol during the riot and an additional 13 entered a restricted area around the Capitol. But none were authorized to do so by the FBI, nor were they given permission to break other laws or encourage others to do the same. The remaining nine informants did not engage in any illegal activities. None of the 17 informants who entered the Capitol or surrounding restricted area have been prosecuted, the report says. A footnote states that after reviewing a draft of the report, the U.S. attorney's office in Washington said that it “generally has not charged those individuals whose only crime on January 6, 2021 was to enter restricted grounds surrounding the Capitol, which has resulted in the Office declining to charge hundreds of individuals; and we have treated the CHSs consistent with this approach.” The assistant special agent in charge of the Washington Field Office's counterterrorism division told the inspector general's office that he “denied a request from an FBI office to have an undercover employee engage in investigative activity on January 6.” He, along with then-Washington Field Office Assistant Director in Charge Steven D'Antuono, said that FBI policy prohibits undercover employees at First Amendment-protected events without investigative authority. Many social media users drew false conclusions from the report's findings. “JANUARY 6th WAS A SETUP!" reads one X post that had received more than 11,400 likes and shares as of Friday. “New inspector general report shows that 26 FBI/DOJ confidential sources were in the crowd on January 6th, and some of them went into the Capitol and restricted areas. Is it a coincidence that Wray put in his resignation notice yesterday? TREASON!” The mention of Wray's resignation refers to FBI Director Christopher Wray's announcement Wednesday that he plans to resign at the end of President Joe Biden's term in January. Other users highlighted the fact that there were 26 FBI informants in Washington on Jan. 6, but omitted key information about the findings of the report. These claims echo a fringe conspiracy theory advanced by some Republicans in Congress that the FBI played a role in instigating the events of Jan. 6, 2021, when rioters determined to overturn Republican Donald Trump's 2020 election loss to Democrat Joe Biden stormed the Capitol in a violent clash with police. The report knocks that theory down. Wray called such theories “ludicrous” at a congressional hearing last year. Asked for comment on the false claims spreading online, Stephanie Logan, a spokesperson for the inspector general’s office, pointed The Associated Press to a press release about the report. In addition to its findings about the the FBI's involvement on Jan. 6, the report said that the FBI, in an action its now-deputy director described as a “basic step that was missed,” failed to canvass informants across all 56 of its field offices for any relevant intelligence ahead of time. That was a step, the report concluded, “that could have helped the FBI and its law enforcement partners with their preparations in advance of January 6.” However, it did credit the bureau for preparing for the possibility of violence and for trying to identify known “domestic terrorism subjects” who planned to come to Washington that day. The FBI said in a letter responding to the report that it accepts the inspection general’s recommendation “regarding potential process improvements for future events.” — Find AP Fact Checks here: https://apnews.com/APFactCheck .Taylor Swift sends fans in frenzy with highly anticipated Easter EggFortinet ( NASDAQ:FTNT – Free Report ) had its price objective boosted by BMO Capital Markets from $88.00 to $100.00 in a report issued on Tuesday, MarketBeat reports. BMO Capital Markets currently has a market perform rating on the software maker’s stock. FTNT has been the topic of a number of other reports. Wells Fargo & Company raised their price target on shares of Fortinet from $62.00 to $64.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 7th. Piper Sandler raised their price target on shares of Fortinet from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Morgan Stanley raised their price target on shares of Fortinet from $105.00 to $106.00 and gave the company an “overweight” rating in a research note on Tuesday. Needham & Company LLC restated a “hold” rating on shares of Fortinet in a research note on Monday, November 11th. Finally, DZ Bank upgraded shares of Fortinet from a “sell” rating to a “hold” rating and set a $65.00 target price on the stock in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $88.93. Read Our Latest Research Report on Fortinet Fortinet Price Performance Insider Buying and Selling at Fortinet In other news, CFO Keith Jensen sold 4,250 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $90.83, for a total value of $386,027.50. Following the completion of the sale, the chief financial officer now owns 4,689 shares in the company, valued at $425,901.87. This represents a 47.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . Also, CEO Ken Xie sold 23,307 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $81.89, for a total transaction of $1,908,610.23. Following the completion of the sale, the chief executive officer now owns 48,915,530 shares of the company’s stock, valued at approximately $4,005,692,751.70. The trade was a 0.05 % decrease in their position. The disclosure for this sale can be found here . In the last 90 days, insiders sold 51,095 shares of company stock worth $4,058,575. 18.00% of the stock is owned by corporate insiders. Institutional Trading of Fortinet Several institutional investors have recently made changes to their positions in FTNT. Eastern Bank bought a new position in shares of Fortinet during the 3rd quarter valued at approximately $25,000. Ashton Thomas Securities LLC bought a new position in shares of Fortinet during the 3rd quarter valued at approximately $26,000. Private Wealth Management Group LLC grew its position in shares of Fortinet by 73.3% during the 3rd quarter. Private Wealth Management Group LLC now owns 409 shares of the software maker’s stock valued at $32,000 after acquiring an additional 173 shares during the period. City State Bank grew its position in shares of Fortinet by 900.0% during the 3rd quarter. City State Bank now owns 500 shares of the software maker’s stock valued at $39,000 after acquiring an additional 450 shares during the period. Finally, Oakworth Capital Inc. bought a new position in shares of Fortinet during the 2nd quarter valued at approximately $33,000. Institutional investors own 83.71% of the company’s stock. Fortinet Company Profile ( Get Free Report ) Fortinet, Inc provides cybersecurity and convergence of networking and security solutions worldwide. It offers secure networking solutions focus on the convergence of networking and security; network firewall solutions that consist of FortiGate data centers, hyperscale, and distributed firewalls, as well as encrypted applications; wireless LAN solutions; and secure connectivity solutions, including FortiSwitch secure ethernet switches, FortiAP wireless local area network access points, FortiExtender 5G connectivity gateways, and other products. Featured Articles Five stocks we like better than Fortinet How to Invest in Small Cap Stocks Tesla Investors Continue to Profit From the Trump Trade 2 Rising CRM Platform Stocks That Can Surge Higher in 2025 MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally What is the Hang Seng index? Netflix Ventures Into Live Sports, Driving Stock Momentum Receive News & Ratings for Fortinet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortinet and related companies with MarketBeat.com's FREE daily email newsletter .
Germany to tighten criminal law as people-smuggling ‘action plan’ agreed with UKHankyung.com introduces: MecKare, Leading the AI-powered Innovation in Health Monitoring Solution
By MICHAEL R. SISAK and JENNIFER PELTZ NEW YORK (AP) — President-elect Donald Trump’s lawyers urged a judge again Friday to throw out his hush money conviction, balking at the prosecution’s suggestion of preserving the verdict by treating the case the way some courts do when a defendant dies. They called the idea “absurd.” Related Articles National Politics | Trump wants to turn the clock on daylight saving time National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, District Attorney Alvin Bragg’s office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. They include freezing the case until Trump leaves office in 2029, agreeing that any future sentence won’t include jail time, or closing the case by noting he was convicted but that he wasn’t sentenced and his appeal wasn’t resolved because of presidential immunity. Trump lawyers Todd Blanche and Emil Bove reiterated Friday their position that the only acceptable option is overturning his conviction and dismissing his indictment, writing that anything less will interfere with the transition process and his ability to lead the country. The Manhattan district attorney’s office declined comment. It’s unclear how soon Merchan will decide. He could grant Trump’s request for dismissal, go with one of the prosecution’s suggestions, wait until a federal appeals court rules on Trump’s parallel effort to get the case moved out of state court, or choose some other option. In their response Friday, Blanche and Bove ripped each of the prosecution’s suggestions. Halting the case until Trump leaves office would force the incoming president to govern while facing the “ongoing threat” that he’ll be sentenced to imprisonment, fines or other punishment as soon as his term ends, Blanche and Bove wrote. Trump, a Republican, takes office Jan. 20. “To be clear, President Trump will never deviate from the public interest in response to these thuggish tactics,” the defense lawyers wrote. “However, the threat itself is unconstitutional.” The prosecution’s suggestion that Merchan could mitigate those concerns by promising not to sentence Trump to jail time on presidential immunity grounds is also a non-starter, Blanche and Bove wrote. The immunity statute requires dropping the case, not merely limiting sentencing options, they argued. Blanche and Bove, both of whom Trump has tabbed for high-ranking Justice Department positions, expressed outrage at the prosecution’s novel suggestion that Merchan borrow from Alabama and other states and treat the case as if Trump had died. Blanche and Bove accused prosecutors of ignoring New York precedent and attempting to “fabricate” a solution “based on an extremely troubling and irresponsible analogy between President Trump” who survived assassination attempts in Pennsylvania in July and Florida in September “and a hypothetical dead defendant.” Such an option normally comes into play when a defendant dies after being convicted but before appeals are exhausted. It is unclear whether it is viable under New York law, but prosecutors suggested that Merchan could innovate in what’s already a unique case. “This remedy would prevent defendant from being burdened during his presidency by an ongoing criminal proceeding,” prosecutors wrote in their filing this week. But at the same time, it wouldn’t “precipitously discard” the “meaningful fact that defendant was indicted and found guilty by a jury of his peers.” Prosecutors acknowledged that “presidential immunity requires accommodation” during Trump’s impending return to the White House but argued that his election to a second term should not upend the jury’s verdict, which came when he was out of office. Longstanding Justice Department policy says sitting presidents cannot face criminal prosecution . Other world leaders don’t enjoy the same protection. For example, Israeli Prime Minister Benjamin Netanyahu is on trial on corruption charges even as he leads that nation’s wars in Lebanon and Gaza . Trump has been fighting for months to reverse his May 30 conviction on 34 counts of falsifying business records . Prosecutors said he fudged the documents to conceal a $130,000 payment to porn actor Stormy Daniels to suppress her claim that they had sex a decade earlier, which Trump denies. In their filing Friday, Trump’s lawyers citing a social media post in which Sen. John Fetterman used profane language to criticize Trump’s hush money prosecution. The Pennsylvania Democrat suggested that Trump deserved a pardon, comparing his case to that of President Joe Biden’s pardoned son Hunter Biden, who had been convicted of tax and gun charges . “Weaponizing the judiciary for blatant, partisan gain diminishes the collective faith in our institutions and sows further division,” Fetterman wrote Wednesday on Truth Social. Trump’s hush money conviction was in state court, meaning a presidential pardon — issued by Biden or himself when he takes office — would not apply to the case. Presidential pardons only apply to federal crimes. Since the election, special counsel Jack Smith has ended his two federal cases , which pertained to Trump’s efforts to overturn his 2020 election loss and allegations that he hoarded classified documents at his Mar-a-Lago estate. A separate state election interference case in Fulton County, Georgia, is largely on hold. Trump denies wrongdoing in all. Trump had been scheduled for sentencing in the hush money case in late November. But following Trump’s Nov. 5 election victory, Merchan halted proceedings and indefinitely postponed the former and future president’s sentencing so the defense and prosecution could weigh in on the future of the case. Merchan also delayed a decision on Trump’s prior bid to dismiss the case on immunity grounds. A dismissal would erase Trump’s conviction, sparing him the cloud of a criminal record and possible prison sentence. Trump is the first former president to be convicted of a crime and the first convicted criminal to be elected to the office.
Banque Cantonale Vaudoise acquired a new stake in Paramount Global ( NASDAQ:PARA – Free Report ) in the third quarter, Holdings Channel.com reports. The fund acquired 21,059 shares of the company’s stock, valued at approximately $224,000. A number of other institutional investors have also modified their holdings of the company. Great Valley Advisor Group Inc. grew its stake in shares of Paramount Global by 5.3% in the second quarter. Great Valley Advisor Group Inc. now owns 19,940 shares of the company’s stock valued at $207,000 after buying an additional 1,002 shares in the last quarter. Carson Advisory Inc. grew its stake in Paramount Global by 1.9% during the 3rd quarter. Carson Advisory Inc. now owns 54,364 shares of the company’s stock worth $577,000 after purchasing an additional 1,004 shares in the last quarter. Prestige Wealth Management Group LLC grew its stake in Paramount Global by 13.2% during the 2nd quarter. Prestige Wealth Management Group LLC now owns 8,648 shares of the company’s stock worth $90,000 after purchasing an additional 1,011 shares in the last quarter. GAMMA Investing LLC grew its stake in Paramount Global by 22.8% during the 2nd quarter. GAMMA Investing LLC now owns 5,742 shares of the company’s stock worth $60,000 after purchasing an additional 1,067 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. grew its stake in Paramount Global by 8.4% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 17,411 shares of the company’s stock worth $181,000 after purchasing an additional 1,356 shares in the last quarter. 73.00% of the stock is owned by institutional investors and hedge funds. Paramount Global Stock Down 1.9 % Paramount Global stock opened at $10.88 on Friday. Paramount Global has a fifty-two week low of $9.54 and a fifty-two week high of $17.50. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.10 and a current ratio of 1.27. The company has a market capitalization of $7.26 billion, a P/E ratio of -1.32, a PEG ratio of 1.25 and a beta of 1.74. The stock has a 50-day simple moving average of $10.66 and a 200-day simple moving average of $11.01. Paramount Global Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 16th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 1.84%. The ex-dividend date is Monday, December 16th. Paramount Global’s dividend payout ratio is presently -2.43%. Analysts Set New Price Targets Several research analysts recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Paramount Global in a research note on Monday, November 11th. Macquarie reissued an “underperform” rating and set a $10.00 target price on shares of Paramount Global in a research note on Monday, November 11th. Benchmark reissued a “buy” rating and set a $19.00 target price on shares of Paramount Global in a research note on Friday, August 9th. Wells Fargo & Company raised Paramount Global from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $10.00 to $11.00 in a research report on Friday, August 9th. Finally, StockNews.com raised Paramount Global from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. Eight research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Paramount Global has an average rating of “Hold” and an average price target of $12.40. Read Our Latest Report on PARA Paramount Global Profile ( Free Report ) Paramount Global operates as a media, streaming, and entertainment company worldwide. It operates through TV Media, Direct-to-Consumer, and Filmed Entertainment segments. The TV Media segment operates CBS Television Network, a domestic broadcast television network; CBS Stations, a television station; and international free-to-air networks comprising Network 10, Channel 5, Telefe, and Chilevisión; domestic premium and basic cable networks, such as Paramount+ with Showtime, MTV, Comedy Central, Paramount Network, The Smithsonian Channel, Nickelodeon, BET Media Group, and CBS Sports Network; and international extensions of these brands. Recommended Stories Want to see what other hedge funds are holding PARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paramount Global ( NASDAQ:PARA – Free Report ). Receive News & Ratings for Paramount Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paramount Global and related companies with MarketBeat.com's FREE daily email newsletter .M/I Homes CEO Robert Schottenstein sells $2 million in stock
None
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseida) (NASDAQ: PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Blue Giant Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and Poseida. The tender offer period will expire at one minute following 11:59 p.m., New York City time on 7 January, 2025, unless the offer is extended. Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission (SEC). Blue Giant Acquisition Corp. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer. Poseida has also filed a Solicitation/Recommendation Statement with the SEC on Schedule 14D-9, which includes the unanimous recommendation of the Poseida board of directors that Poseida stockholders tender their shares in the tender offer. Closing of the tender offer is conditioned upon customary closing conditions, including the receipt of required regulatory approvals, and there being validly tendered and not validly withdrawn a majority of the outstanding shares of Poseida common stock. The offer is not subject to any financing condition. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second step merger at the same price of $9.00 per share, plus the CVR. The closing of the transaction is expected to take place in the first quarter of 2025. The complete terms and conditions are set out in the Offer to Purchase, which was filed with the SEC today, December 9, 2024. Poseida stockholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC’s website (www.sec.gov) or by directing a request for the Solicitation/Recommendation Statement on Schedule 14D-9 to Poseida’s website at www.poseida.com or the Offer to Purchase and the other related materials to MacKenzie Partners, Inc., the Information Agent for the offer, toll free at (800) 322-2885 (or please call (212) 929-5500 if you are located outside the U.S. or Canada) or via email at tenderoffer@mackenziepartners.com. Before making any decision with respect to the Offer, investors are urged to read the Offer to Purchase and related documents, as well as the Solicitation/Recommendation Statement, because they contain important information about the Offer. About Poseida Therapeutics Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company’s pipeline includes investigational allogeneic CAR-T cell therapies for hematologic cancers, autoimmune diseases, and solid tumours, as well as investigational in vivo genetic medicines that address patient populations with high unmet medical need. The Company’s approach is based on its proprietary genetic editing platforms, including its non-viral transposon-based DNA delivery system, Cas-CLOVERTM Site-Specific Gene Editing System Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. The Company has formed strategic collaborations with Roche and Astellas to unlock the promise of cell therapies for cancer patients. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com . All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Roche Investor Relations Investor Relations North America Cautionary Statement Regarding Forward-Looking Statements This communication may include statements that are not statements of historical fact, or “forward-looking statements,” within the meaning of the federal securities laws, including with respect to Roche’s proposed acquisition of Poseida. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. These statements are generally identified by words or phrases such as “believe”, “anticipate”, “expect”, “intend”, “plan”, “will”, “may”, “should”, “estimate”, “predict”, “project”, “strategy”, “potential”, “continue” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, the ability of Roche and Poseida to complete the transactions contemplated by the merger agreement, including each party’s ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement and statements about the expected timetable for completing the transaction. These statements are based upon the current beliefs and expectations of Roche and Poseida’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable if at all. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements, and you should not place undue reliance on these statements. Risks and uncertainties include, but are not limited to, uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Poseida’s stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the offer and the merger contemplated by the merger agreement may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the tender offer or the subsequent merger; the ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Poseida’s business; the possibility that the milestone payments related to the contingent value right will never be achieved and that no milestone payment may be made; and the risk of legal proceedings being brought in relation to the transactions and the outcome of such proceedings, including the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. The foregoing factors should be read in conjunction with the risks and cautionary statements discussed or identified in Poseida’s public filings with the SEC, including the “Risk Factors” section of Poseida’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q, Form 8-K and in other filings Poseida makes with the SEC from time to time as well as the tender offer materials to be filed by Roche and its acquisition subsidiary and the Solicitation/Recommendation Statement to be filed by Poseida, in each case as amended by any subsequent filings made with the SEC. Neither Roche nor Poseida undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Attachment 09122024_Poseida Trade Offer_enM/I Homes CEO Robert Schottenstein sells $934,547 in stockNew York Jets ' interim head coach Jeff Ulbrich provided fantasy football managers with a piece of good news on Friday afternoon in Florham Park, updating running back Breece Hall's Week 15 status. "Breece, he looks good right now, so it's promising," said Ulbrich. After back-to-back days as a non-participant , Hall practiced fully in an indication that the RB1 will be available for the December 15 road test against the Jacksonville Jaguars. He did not practice leading up to the Week 14 trip to Miami and was listed as doubtful before missing a game for the first time this season. Hall's knee issue dates back multiple weeks. After the bye, he was questionable to face the Seattle Seahawks on December 1 and wound up playing 62 percent of snaps while rushing 12 times for 60 yards. Over 12 games, Hall had totaled 1,093 yards from scrimmage and six touchdowns. As of now, there is no plan to shut Hall down prematurely. "If there was a structural problem, from the standpoint of impacting his future with this team or his future for his career, we would definitely shut him down, if it was in the best interest of Breece. We're not at that point right now, so we'll see how it goes," said Ulbrich. Rookies Braelon Allen and Isaiah Davis carried the load in Hall's absence on December 8 against the Dolphins. The two combined for combined to rush for 83 yards rushing and 65 yards receiving. The Jets' next opponent features the NFL's worst-ranked defense on multiple fronts. The Jaguars surrender 396.1 yards per game, 5.97 yards per play and 7.77 yards per pass play - all league worsts. The Jets (3-10) and the Jaguars (3-10) will kick off at 1 p.m. ET on Sunday in Jacksonville. More New York Jets News: • Jets lose Pro Bowl candidate for rest of season due to ACL injury • Aaron Rodgers claims NFL insider 'doesn't know s–t about my body' • Extending leading tackler tabbed as immediate priority for Jets' front office • Jets' healthy scratch becoming another Joe Douglas draft failure • Davante Adams critiques officials for costly late-game blunder in MiamiStock market today: Wall Street hits records despite tariff talk
None
An international crime ring may be behind burglaries targeting the homes of professional athletes across the US, although experts caution that local groups could also be responsible. In recent weeks, several NFL players and an NBA player have been robbed while traveling for games, including Kansas City Chiefs player Travis Kelce and his teammate Patrick Mahomes. The FBI is investigating whether the burglaries could be connected to a transnational crime operation with links to South America, a source familiar with the investigation told the BBC's US partner CBS News. "It's a transnational crime ring, and over the last three weeks, they've focused on NBA and NFL players, and it's all over the country," a source familiar with the situation told NFL.com. But Michael Tabman, a former FBI special agent, said there could be a simpler explanation. "It could be possible that you have some capable burglars in Kansas City who maybe have some inside information," he said. "And you'll notice, when a crime starts getting covered a lot, it starts popping up elsewhere, so like a copycat." The BBC has contacted the FBI and Kansas City police for comment. The burglaries have been taking place across the country. Kelce's home was robbed on 7 October as he was starting a game against the New Orleans Saints. Officials said $20,000 (£15,900) in cash was stolen from his $6m home. A burglary was also discovered at Dallas Cowboys player Linval Joseph’s home on Monday, while Milwaukee Bucks forward Bobby Portis was robbed earlier this month. The athletes make for easy targets in part because they have valuable belongings and public schedules, security experts said. "In any professional football event, for instance, there's 106 players, 53 on each team, that are not going to be home, not including coaches. And some of those players may have very lucrative contracts and live in nice places," said former FBI agent Jeff Lanza. The NFL has been warning players about the crimes, sending a memo this week which said "organised and skilled groups" appeared to be targeting them. The memo said the groups were tracking the players' whereabouts on social media and through public records. It said criminals had been conducting surveillance by posing as joggers, maintenance workers or delivery people, eventually gaining access to the homes through side doors or even scaling walls to get through windows and balconies. Those details suggests the criminals have some level of sophistication, Mr Lanza said. "You'd have to have people that would maybe do some surveillance to see the comings and goings of the potential targets, that no one else is home, maybe people to understand if there's an alarm system that's been employed," he said. Mr Lanza said the FBI's involvement in the investigation - which would normally be handled by local officials - suggests the crimes are "more orchestrated and organised and tied to a bigger organisation". But other explanations are also likely, he said. "It could be some punks that just know the Chiefs are playing that day and that Patrick Mahomes and Kelce are going to be at the stadium, along with their families, because they show them on TV," he said. Mr Tabman, meanwhile, said law enforcement are likely to catch whoever is behind the thefts, especially if they are able to track down items that were stolen and are being sold. Police have already found a watch stolen from Kelce's Missouri home, ABC News reported. “You'll pull on that one thread that will make this unravel," Mr Tabman said. "It won't happen tomorrow, but I believe there's a very good chance that the FBI, in co-operation with local law enforcement, will be able to break the case."
- Previous:
- Next: 11 vipph casino login
